Therefore we can speculate that, the administration of tamoxifen, a selective estrogen receptor (ER) modulator used in the treatment of ER-positive BC, could inhibit Fra-2 activation in tumor associated fibroblasts, eventually exerting an anti-fibrotic property on the TME [9]. Here, ESR1 is linked to breast cancer.